A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study.
Journal
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
pubmed:
12
12
2020
medline:
27
3
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
Regions within England, Scotland and Wales show variation in rate of adoption of biosimilar infliximab and etanercept. This study aims to examine how local decisions and practices in regions within England, Scotland and Wales might explain initial variation in market dynamics of biosimilar and originator infliximab and etanercept. Market data provided by the National Health Service (NHS) on biosimilar and originator infliximab and etanercept uptake were analysed for the 10 historical regions of England, 14 health boards in Scotland and 7 health boards in Wales (2015-2018). Findings were discussed in ten semi-structured interviews: on a national level with an industry representative (1), on a regional level with NHS employees in England (6), Scotland (1) and Wales (1), and on a local level with a representative of a clinical commissioning group in England (1). Tenders for infliximab and etanercept in England, Scotland and Wales have consistently resulted in a biosimilar as the best value biological. Early and late biosimilar adopters are seen, with overall convergence towards high biosimilar market shares over time. Qualitative results suggest that biosimilar adoption was positively influenced by (a) a price difference between biosimilar and originator product making it worthwhile to switch patients; (b) a good relationship between commissioner and provider in England resulting in gain share agreements; (c) leadership on biosimilars in regional NHS offices in England or Scottish and Welsh health boards; (d) key opinion leaders or leading hospitals that start using biosimilars early and gain experience. This study has shown that the savings potential drives biosimilar use. Regions with a proactive attitude, good stakeholder relationships, and clinician engagement were identified as early adopters.
Sections du résumé
BACKGROUND
BACKGROUND
Regions within England, Scotland and Wales show variation in rate of adoption of biosimilar infliximab and etanercept.
OBJECTIVES
OBJECTIVE
This study aims to examine how local decisions and practices in regions within England, Scotland and Wales might explain initial variation in market dynamics of biosimilar and originator infliximab and etanercept.
METHODS
METHODS
Market data provided by the National Health Service (NHS) on biosimilar and originator infliximab and etanercept uptake were analysed for the 10 historical regions of England, 14 health boards in Scotland and 7 health boards in Wales (2015-2018). Findings were discussed in ten semi-structured interviews: on a national level with an industry representative (1), on a regional level with NHS employees in England (6), Scotland (1) and Wales (1), and on a local level with a representative of a clinical commissioning group in England (1).
RESULTS
RESULTS
Tenders for infliximab and etanercept in England, Scotland and Wales have consistently resulted in a biosimilar as the best value biological. Early and late biosimilar adopters are seen, with overall convergence towards high biosimilar market shares over time. Qualitative results suggest that biosimilar adoption was positively influenced by (a) a price difference between biosimilar and originator product making it worthwhile to switch patients; (b) a good relationship between commissioner and provider in England resulting in gain share agreements; (c) leadership on biosimilars in regional NHS offices in England or Scottish and Welsh health boards; (d) key opinion leaders or leading hospitals that start using biosimilars early and gain experience.
CONCLUSIONS
CONCLUSIONS
This study has shown that the savings potential drives biosimilar use. Regions with a proactive attitude, good stakeholder relationships, and clinician engagement were identified as early adopters.
Identifiants
pubmed: 33306186
doi: 10.1007/s40259-020-00456-5
pii: 10.1007/s40259-020-00456-5
pmc: PMC7803694
doi:
Substances chimiques
Biosimilar Pharmaceuticals
0
Infliximab
B72HH48FLU
Etanercept
OP401G7OJC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-87Références
Int J Pharm Pract. 2019 Apr;27(2):214-217
pubmed: 30160324
BioDrugs. 2017 Dec;31(6):533-544
pubmed: 29127626
BioDrugs. 2019 Jun;33(3):285-297
pubmed: 30945207
Healthc Policy. 2020 Feb;15(3):16-27
pubmed: 32176608
Acta Clin Belg. 2020 May 13;:1-12
pubmed: 32400319
Health Syst Transit. 2015;17(5):1-126
pubmed: 27049966
BMJ Open. 2017 Jun 21;7(6):e016730
pubmed: 28637743
Int J Clin Pharm. 2017 Oct;39(5):1055-1060
pubmed: 28871421
PLoS One. 2017 Dec 28;12(12):e0190147
pubmed: 29284064
J Crohns Colitis. 2017 Jun 1;11(6):690-696
pubmed: 28130330
Pharmaceuticals (Basel). 2020 Oct 21;13(10):
pubmed: 33096709
Res Social Adm Pharm. 2019 Mar;15(3):310-317
pubmed: 29807834
BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
BioDrugs. 2017 Oct;31(5):439-446
pubmed: 28752242
BioDrugs. 2019 Jun;33(3):299-306
pubmed: 30945206
BMJ. 2000 Jan 8;320(7227):114-6
pubmed: 10625273
Front Endocrinol (Lausanne). 2018 Mar 13;9:95
pubmed: 29593655
BMJ Open. 2018 Nov 18;8(11):e023603
pubmed: 30455389
BMJ Open. 2017 Apr 11;7(4):e013730
pubmed: 28400458
BioDrugs. 2016 Aug;30(4):295-306
pubmed: 27138636